American startup biotechnologys Loyal plans to launch a drug that lengthens the duration of life in dogs in early 2025, opening a chapter that, if nothing else, will give us more information about human longevity as well. 
Η company with its registered office San Francisco has secured $125 million in funding for LOY-002, a beef-flavored daily pill designed to extend a dog's lifespan by at least a year.
The drug works by targeting age-related metabolic changes and insulin regulation, according to Loyal CEO Celine Halioua.
At the same time, the Dog Aging Project is studying rapamycin, an immunosuppressant drug, which preliminary research suggests could add three years to dogs' lives.
The researchers believe these dog studies could accelerate research into longevity in humans, although experts say the lack of standardized biomarkers agings remains a major hurdle for drug testing in humans.
